Get In Touch
info@pbgbiopharma.com
Work Inquiries
info@pbgbiopharma.com

THCA as Potential Treatment for Liver Fibrosis

Cannabis and cannabinoids have been suggested as a potential therapy for liver disease. The principal causes for chronic liver disease are viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). Obesity is an increasing common cause for NAFLD due to excessive accumulation of triglycerides in liver, which leads to inflammation and variable degrees of liver fibrosis overtime, eventually causing steatohepatitis.

One recent animal study showed that non-psychoactive THCA, the most abundant natural cannabinoid and precursor of THC in cannabis plants, significantly reduced body weight, improved glucose tolerance, and drastically attenuated liver fibrosis and inflammation in obesity induced NAFLD.

 

Read more here: https://pbgcannabis.com/blog 

 

Reference(s):

https://pubmed.ncbi.nlm.nih.gov/33341026/

close

The freshest cannabis content, right to your inbox.

Sign up to receive the latest developments in cannabis science every week.

We don’t spam! Read our privacy policy for more info.

Author avatar
Dr. Dan Jin
Dr. Dan Jin is the resident Cannabis Research Scientist at PBG BioPharma. She has over 10 publications to her name in the field of cannabis research. She is a passionate force in researching novel uses of cannabis and educating the public about the potential of this incredible plant.

Post a comment

Your email address will not be published. Required fields are marked *

We use cookies to give you the best experience.